Unrelated donor cord blood transplantation (CBT) results in disease-free survival
comparable to that of unrelated adult donor transplantation in patients with hematologic …

Acute myeloid leukemia is the most common indication for an allogeneic hematopoietic cell
transplant. The introduction of reduced intensity conditioning has expanded the recipient …

We studied adults with acute myeloid leukemia (AML) after haploidentical (n= 192) and 8/8
HLA-matched unrelated donor (n= 1982) transplantation. Haploidentical recipients received …

Abstract Approximately 20,000 hematopoietic cell transplantation (HCT) procedures are
performed in the United States annually. With advances in transplantation technology and …

The success of allogeneic hematopoietic cell transplantation (HCT) is typically assessed as
individual complications, including graft-versus-host disease (GVHD), relapse, or death, yet …

The preferred post-remission therapy for older patients with acute myeloid leukemia (AML)
in first complete remission (CR1) remains uncertain. In this retrospective, multicenter study …

Slow immune reconstitution is a major obstacle to the successful use of allogeneic
hematopoietic cell transplantation (allo-HCT). As matched sibling donor (MSD) allo-HCT is …

The role of hematopoietic cell transplantation (HCT) in the management of newly diagnosed
adult acute myeloid leukemia (AML) is reviewed and critically evaluated in this evidence …

It has recently been shown that a T cell–replete allogeneic (allo) hematopoietic stem cell
transplantation (HSCT) from a haploidentical donor (haplo-ID) could be a valid treatment for …

Allogeneic hematopoietic cell transplantation is often complicated by graft-versus-host
disease (GVHD). We analyzed the incidences and risk factors for acute (aGVHD) and …